g0d4ather-shutterstock-com-amgen-

g0d4ather / Shutterstock.com

3 October 2016Americas

Amgen and Arrowhead agree RNAi development deal

Biopharmaceutical company Amgen and drug manufacturer Arrowhead Pharmaceuticals have entered into two agreements to develop and commercialise RNA interference (RNAi) therapies for cardiovascular disease.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic